Alzheimer & Parkinson
CHCHD2 mutant mice link mitochondrial deficits to PD pathophysiology
Mitochondrial dysfunction is a hallmark of Parkinson's disease (PD), but the mechanisms by which it drives autosomal dominant and idiopathic forms of PD remain unclear. To investigate this, we generated and performed a comprehensive phenotypic analysis of a knock-in mouse model carrying the T61I mutation in the mitochondrial protein CHCHD2 (coiled-coil-helix-coiled-coil-helix domain-containing 2), which causes late-onset symptoms indistinguishable from idiopathic PD. We observed pronounced...
Identification of cognitive brain diseases using a dual-branch siamese network on structural magnetic resonance imaging data
Early diagnosis of Alzheimer's Disease is crucial for optimizing treatment efficacy, as delayed detection often limits therapeutic outcomes. Traditional diagnostic approaches, such as cognitive assessments, PET scans, and lumbar punctures, are often invasive, costly, and less accessible. To address these limitations, we propose a Dual-Branch Siamese Network aimed at enhancing the classification accuracy of Alzheimer's Disease, Mild Cognitive Impairment, and Cognitively Normal individuals using...
Single-nucleus multi-omics identifies shared and distinct pathways in Pick's and Alzheimer's disease
The study of transcriptomic and epigenomic variations in neurodegenerative diseases, particularly tauopathies like Pick's disease (PiD) and Alzheimer's disease (AD), offers insights into their underlying regulatory mechanisms. Here, we identified critical regulatory changes driving disease progression, revealing potential therapeutic targets. Our comparative analyses uncovered disease-enriched noncoding regions and genome-wide transcription factor (TF) binding differences, linking them to target...
Three rising stars in ageing research
No abstract
The future of ageing: science aims to deliver another leap in lifespan
No abstract
Is ageing a disease? The debate that could reshape medicine
No abstract
iPEX enables micrometre-resolution deep spatial proteomics via tissue expansion
The number of spatial omics technologies being developed is increasing¹. However, a missing tool is one that can locate proteins in tissues in an untargeted manner at high spatial resolution and coverage. Here we present in situ imaging proteomics via expansion (iPEX), which integrates isotropic tissue magnification² with matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging. iPEX provides scalable spatial resolution down to the micrometre scale and substantially...
Digital dementia and testing of cognitive intervention for degenerating neural networks
The development of effective interventions for neurodegenerative disorders, such as posterior cortical atrophy (a visual Alzheimer's variant), remains to be a significant clinical challenge. We introduce a computational framework using convolutional neural networks (CNNs) as in silico models to simulate visual system degeneration and evaluate intervention strategies. By modeling controlled synaptic decay and comparing three distinct retraining approaches, random data (control), accuracy-based,...
Flipping APOE to reverse Alzheimer's disease traits
No abstract
APOE4 to APOE2 allelic switching in mice improves Alzheimer's disease-related metabolic signatures, neuropathology and cognition
Compared to individuals carrying two copies of the ε4 allele of apolipoprotein E (APOE), ε2 homozygotes have an approximate 99% reduction in late-onset Alzheimer's disease (AD) risk. Here we develop a knock-in model that allows for an inducible 'switch' between risk and protective alleles (APOE4s2). Gene expression and proteomic analyses confirm that APOE4s2 mice synthesize E4 at baseline and E2 after tamoxifen administration. A whole-body allelic switch results in a metabolic profile resembling...
Arabinoxylan ameliorates memory deficits and amyloid pathology in male 5 × FAD mice via modulation of gut microbiota structure
Alzheimer's disease (AD), a prevalent neurodegenerative disorder, is primarily characterized by β-amyloid (Aβ) deposition. Current therapies alleviate symptoms but lack agents capable of modifying disease progression. Meanwhile, cross-regional studies indicate that AD patients exhibit disrupted gut microbiota composition, which is closely associated with cerebral molecular dysregulation. Building on this gut-brain connection, this study aimed to attenuate AD progression by targeting gut...
Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome
Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including n = 2329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the...
Subsecond dopamine fluctuations do not specify the vigor of ongoing actions
Dopamine (DA) is essential for the production of vigorous actions, but how DA modifies the gain of motor commands remains unclear. Here we show that subsecond DA transients in the striatum of mice are neither required nor sufficient for specifying the vigor of ongoing forelimb movements. Our findings have important implications for our understanding of how DA contributes to motor control under physiological conditions and in Parkinson's disease.
Therapeutic VEGFC treatment provides protection against traumatic-brain-injury-driven tauopathy pathogenesis
Traumatic brain injury (TBI) increases one's risk of developing Alzheimer's disease and tauopathy. Yet, the mechanisms linking TBI to neurodegenerative disease remain poorly defined. Mounting recent evidence indicates that defects in brain lymphatic drainage contribute to multiple neurodegenerative diseases. Here, we investigated whether promoting brain lymphatic drainage recuperation following TBI via treatment with the lymphangiogenic factor vessel endothelial growth factor C (VEGFC) mitigates...
Driving forward a new perspective on everyday memory in the real world
No abstract
Serum bile acids and brain hypometabolism in patients across Alzheimer's disease continuum: An [(18)F]FDG-PET study
The present study compares the predictive performance of serum bile acids with that of traditional Cerebrospinal Fluid (CSF) biomarkers for brain hypometabolism in the Alzheimer's disease (AD) continuum using [^(18)F]-Fluorodeoxyglucose Positron Emission Tomography ([^(18)F]-FDG-PET). Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Conventional CSF biomarker data, serum bile acid measurements, and [^(18)F]-FDG-PET data were used. We studied 556 participants,...
Boosting dopamine: Following the lineage toward Parkinson's repair
Low yields of dopamine neurons in human stem cell-derived neural grafts limit their potential for treating Parkinson's disease. Zhang et al.¹ develop a new three-dimensional differentiation method, informed and refined through careful clonal linage tracing of donor cells post-transplantation, to improve dopamine neuron purity of grafts, eliminating unwanted, off-target populations.
Exploring the Causal Relationship between Telomere Regulation, Aging and Neurological Disorders
Telomere biology is important for aging and is the cause of the pathogenesis of many neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), stroke, and brain tumors. Telomere shortening is considered to play a role in neurodegeneration, immune senescence, and cerebrovascular dysfunction. Shorter leukocyte telomere length (LTL) is associated with increased risk and severity of stroke, poorer cognitive outcomes in AD, and increased...
Effects of alpha-Synuclein Immunization in a Mouse Model of Parkinson's Disease
No abstract
Are we ready for a biological diagnosis of Parkinson's Disease?
The diagnosis of Parkinson's disease (PD) is currently based on clinical criteria, centered on the characteristic motor syndrome. However, motor manifestations become evident only after a significant proportion of nigro-striatal dopaminergic neurons have already undergone neurodegeneration. The recent "NSD-ISS" and "SynNeurGe" research frameworks have proposed new biological diagnostic criteria focusing on α-synucleinopathy, neurodegeneration, and genetic biomarkers, independent of clinical...
Alzheimer and Parkinson: Latest results from PubMed
Subscribe to Alzheimer & Parkinson feed